Should Qualigen Therapeutics Inc. (NASDAQ: QLGN) Revive After A -477.78% Drop From Highs? – Marketing Sentinel
Home  »  Technologies   »  Should Qualigen Therapeutics Inc. (NASDAQ: QLGN) R...

Should Qualigen Therapeutics Inc. (NASDAQ: QLGN) Revive After A -477.78% Drop From Highs?

During the last session, Qualigen Therapeutics Inc. (NASDAQ:QLGN)’s traded shares were 0.5 million, with the beta value of the company hitting -0.46. At the end of the trading day, the stock’s price was $0.54, reflecting an intraday gain of 7.65% or $0.04. The 52-week high for the QLGN share is $3.12, that puts it down -477.78 from that peak though still a striking 16.67% gain since the share price plummeted to a 52-week low of $0.45. The company’s market capitalization is $19.24M, and the average intraday trading volume over the past 10 days was 0.24 million shares, and the average trade volume was 1.21 million shares over the past three months.

Qualigen Therapeutics Inc. (NASDAQ:QLGN) trade information

Qualigen Therapeutics Inc. (QLGN) registered a 7.65% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.65% in intraday trading to $0.54 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is 0.30%, and it has moved by -29.32% in 30 days. Based on these gigs, the overall price performance for the year is -65.83%. The short interest in Qualigen Therapeutics Inc. (NASDAQ:QLGN) is 1.8 million shares and it means that shorts have 0.09 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Qualigen Therapeutics Inc. (QLGN) estimates and forecasts

Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -123.50% this quarter and then drop -23.10% in the quarter after that.

Revenue for the current quarter is expected to be $1.75 million as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to $1.75 million by the end of Mar 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $1.11 million and $1.51 million respectively. In this case, analysts expect current quarter sales to grow by 57.90% and then jump by 15.90% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 65.40%. While earnings are projected to return 45.60% in 2022.

QLGN Dividends

Qualigen Therapeutics Inc. is due to release its next quarterly earnings on November 15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Qualigen Therapeutics Inc. (NASDAQ:QLGN)’s Major holders

Qualigen Therapeutics Inc. insiders own 8.72% of total outstanding shares while institutional holders control 13.67%, with the float percentage being 14.98%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 34 institutions own stock in it. As of Sep 29, 2021, the company held over 1.18 million shares (or 4.00% of all shares), a total value of $1.53 million in shares.

The next largest institutional holding, with 0.33 million shares, is of Blackrock Inc.’s that is approximately 1.13% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $0.43 million.

Also, the Mutual Funds coming in first place with the largest holdings of Qualigen Therapeutics Inc. (QLGN) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Sep 29, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.64 million shares. This amounts to just over 2.17 percent of the company’s overall shares, with a $0.83 million market value. The same data shows that the other fund manager holds slightly less at 0.37 million, or about 1.27% of the stock, which is worth about $0.48 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts